Alphatec Holdings, Inc. (ATEC) is an acclaimed medical technology company headquartered in Carlsbad, California. Committed to revolutionizing the approach to spine surgery, ATEC designs and develops innovative yet safe surgical solutions aimed to improve the lives of patients suffering from spinal disorders.
The company, traded under the ticker symbol 'ATEC' on the NASDAQ Global Market, has keenly positioned itself as a key player in the spine surgery sector. Alphatec's philosophy is centered on a patient-first approach, ensuring their solutions are driven by the needs, safety and well-being of the patients.
The portfolio of ATEC comprises specially-designed spine surgery products including cervico-thoracic, interbody, and biologic solutions along with comprehensive intraoperative neuromonitoring services. The company's innovative products aim to streamline the surgical process while delivering effective patient outcomes each time. Integral to their mission is a commitment to both innovate and strive for clinical distinction, with the main goal of altering the standards of care in spinal surgery.
In their constant endeavor to revolutionize spine surgery, Alphatec continues to invest considerably in research and development. Their dedicated team of highly qualified professionals work together to discover newer, safer, and more effective surgical solutions to spine-related problems.
They are also known for their active engagement in clinical education, driving forward the industry's technical knowledge. Additionally, the company supports the medical community's ongoing learning and development by participating in various educational programs and providing product training.
In their quest to provide more personalized and effective treatment solutions for patients suffering from spine disorders, Alphatec has also integrated data analytics and machine learning in their product development phase. This approach allows for a more comprehensive understanding of spinal disorders and facilitates the development of products specifically tailored to address specific problems.
It's worth noting that Alphatec's success is not only marked by their globally recognized surgical solutions but also by their business acumen and corporate responsibility. They have demonstrated a commitment to ethical business practices, maintaining a high standard of corporate governance which has played a key role in their growth and sustained industry position.
In conclusion, Alphatec Holdings, Inc. (ATEC), with its innovative and patient centric approach, continues to make significant waves in the global medical technology industry, specifically in the spine surgery sector. Patient well-being remains at heart of their business, driving them to continuously innovate, improve, and contribute to medical advancements in the best possible manner.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alphatec (ATEC) shares jumped 19.7% following strong Q2 2026 performance, with earnings of 7 cents per share and revenues of $213.5 million. The company maintains its full-year 2026 revenue guidance of approximately $882 million due to solid case volume growth and surgeon adoption. Despite the recent surge, the stock, currently holding a Zacks Rank #3 (Hold), faces uncertainty as its consensus EPS estimate for the upcoming quarter has remained unchanged, suggesting that continued strength might depend on future earnings estimate revisions.
Alphatec Holdings (ATEC) recently saw increased market attention due to a firm advance in its stock, renewing focus on its spine-surgery technology business. The company's market activity was directly linked to its healthcare profile, separating its performance from the broader market rebound. This interest was further supported by easing energy concerns and inflation updates that met expectations in the wider US equities market.
This article analyzes Alphatec Holdings Inc. (NASDAQ: ATEC) volatility, indicating weak sentiment across all time horizons which supports a short bias. It outlines institutional trading strategies including a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, each with specific entry, target, and stop-loss levels. The analysis emphasizes a high risk-reward short setup with a 30.7% downside target.
This article provides an in-depth analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It details various institutional trading strategies, including position trading, momentum breakout, and risk hedging, based on AI-generated signals. The analysis also includes multi-timeframe signal strengths and key support/resistance levels for ATEC.
Alphatec Holdings (ATEC) saw its stock rise by 5.9% after announcing Q2 results that showed a narrowed net loss and reaffirmed its 2026 revenue guidance of approximately US$882 million. The company also filed an US$8.12 million shelf registration related to an ESOP offering. This positive movement is attributed to management's continued focus on cost discipline and growth initiatives, reinforcing the company's investment narrative of achieving sustained profitability through its spine portfolio and EOS ecosystem.
HC Wainwright analysts have raised their Q3 2026 EPS estimate for Alphatec (NASDAQ:ATEC) to a loss of $0.02 from $0.06, maintaining a "Buy" rating and a $24 price target. The firm anticipates Alphatec will achieve positive quarterly earnings in 2027, projecting EPS between $0.08 and $0.18, and further growth to $0.79 in 2028 and $1.05 in 2029. Despite a recent strong revenue report, the company remains unprofitable overall, with a consensus "Moderate Buy" rating from analysts and an average price target of $17.40.
HC Wainwright has reduced its FY2027 earnings per share (EPS) estimate for Alphatec to $0.47 from $0.59, while reiterating a "Buy" rating and a $24 price target. This revision follows Alphatec's recent quarterly earnings which met EPS expectations of $0.07 and surpassed revenue forecasts with $213.51 million, marking a 15.1% year-over-year increase. Despite the lowered earnings forecast, analyst sentiment remains largely positive for the medical technology company.
Alphatec (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 8,168 shares of the company's stock, valued at $78,821.20, on August 5th. This transaction was part of a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations from vested equity awards. Despite this insider sale, Alphatec holds a "Moderate Buy" consensus rating from analysts with an average price target of $17.40, significantly higher than its current trading price of $9.31.